$FTRE

SANDERS MACHELLE sold $175K of FTRE

SANDERS MACHELLE sold 9,700 shares of Fortrea Holdings Inc. (FTRE) at $18.01 ($0.17M total) on 2026-08-03.

Original reporting
SEC EDGAR · SANDERS MACHELLE
Published Aug 5, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 6:29 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$FTRE
Neutral
low confidence
Mentioned
$FTRE
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$FTRENeutralLow
01

Why it matters

The disclosure updates the record of insider ownership and may influence short-term sentiment, but it does not include any new company fundamentals.

02

Market read

Traders may note insider selling, but absent additional fundamental catalysts, the event is unlikely to drive a major repricing.

03

What to watch

The article does not state whether the sale was part of a 10b5-1 plan (it says no), but it also provides no context on motivations or other concurrent insider activity.

Relevance 4/10Novelty 3/10Timing: filed 2026-08-05, transaction dated 2026-08-03

Background

This is a SEC Form 4 insider transaction disclosure for Fortrea Holdings Inc.

Company-level read

Ticker impact

$FTRENeutralLow confidence
Context

Fortrea director Sanders Machelle filed a Form 4 selling 9,700 shares at $18.01 on 2026-08-03, totaling about $174.7K.

Expected impact

Low likelihood of a sustained price move; any reaction is likely muted unless accompanied by other disclosures.

Evidence & confidence

The filing is an insider transaction without a 10b5-1 plan and is relatively small versus typical company market caps, with no accompanying operational or guidance change disclosed.

Market effects

No clear sector read-through from a single, small insider sale.

None indicated.

None indicated.

Counterpoint

Insider sales can be driven by diversification, taxes, or pre-existing personal liquidity needs, so the signal may be noise.

Key entities

  • Fortrea Holdings Inc.

    Subject of the Form 4 insider sale by a director.

  • SANDERS MACHELLE

    Director who sold 9,700 shares in an open-market transaction.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$FTREMed

Fortrea (FTRE) Stock Is Up, What You Need To Know

Fortrea Holdings (FTRE) shares rose 2.8% after acquiring Worldwide Clinical Trials' Early Phase Services division, expanding its clinical research capabilities. The acquisition includes facilities in Texas. Fortrea's stock is volatile, with a 52-week high of $20.70. Q3 revenue was $701.3M, beating estimates, but earnings missed. Full-year revenue guidance was raised to $2.73B.

$FTREHigh

Fortrea To Acquire Early Phase Services From Worldwide Clinical Trials; Stock Up

Fortrea Holdings (FTRE) agreed to buy the Early Phase Services division of Worldwide Clinical Trials, including labs and clinical units in Texas. The deal expands Fortrea's early development network, adding bioanalytical and clinical pharmacology capabilities. FTRE shares rose 5.98% to $18.78. According to the company, the acquisition supports growth and increases long-term shareholder value.

$FTREMed

Fortrea Holdings Inc: Fortrea to Acquire Clinical Pharmacology Unit and Bioanalytical Laboratory Operations from Worldwide Clinical Trials

Fortrea (FTRE) will acquire Worldwide Clinical Trials' Early Phase Services division for $45M, including a bioanalytical lab and clinical pharmacology unit. The deal expands Fortrea's early clinical development capabilities, enhancing its platform for Phases I-IV studies. Worldwide will focus on its late-stage business. The transaction is subject to regulatory approvals.